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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
 
 
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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Acronym Definition 
AE 
ACQ 
Adverse events 
Agoraphobic cognitions questionnaire 
AMSTAR Assessing the quality of systematic reviews 
ARM Agnew relationship measure,  
BAI Beck Anxiety Inventory 
BCVA Best corrected visual activity 
BDI 
BRAMES 
BSQ 
Becks depression index 
Bech-Rafaelsen melancholia scale 
Body shape questionnaire 
CBT 
CES-D 
Cognitive based therapy 
Center for epidemiologic studies - depression 
CG 
CGI-S 
Clinical guideline 
Clinical global depression scale - severity 
DH Department of Health 
EQ-5D 
EPDS 
EuroQol 5 dimensions 
Edinburgh postnatal depression scale 
FR Future research 
GAD-7 
GAF 
Generalised Anxiety Disorder Assessment-7 
Global assessment of functioning 
HADS 
HAM-A 
HAM-D 
Hospital anxiety and depression scale 
Hamilton anxiety scale 
Hamilton depression scale 
HRQoL Health related quality of life   
HS Health states 
HTA Health technology assessment 
MADRS 
MBCT 
MDD 
MDE 
MIA 
MIB 
Montgomery-Asberg depression rating scale 
Mindfulness-based cognitive therapy 
Major depressive disorder 
Major depressive episode 
Mobility inventory  W avoidance alone 
Mobility inventory  W avoidance accompanied 
MTA Multiple technology assessment 
NAPT National Audit of Psychological Therapies for Anxiety and Depression 
NCA National Clinical Audit 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
PHQ-9 Patient health questionnaire 
PQWB Psychological General Well-Being Index 
PR Potential recommendations 
PROM(s) patient reported outcome measure(s) 
QALY 
QLDS 
Quality adjusted life year 
Quality of life in depression scale 
R&D Research and development 
RCT Randomised controlled trial 
SCL 
SF-6D 
Symptom checklist 
Short form 36 
SMD 
SR 
Standardised mean difference 
Systematic review 
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SRM Standardised response mean 
TA 
TAU 
Technology Appraisal 
Treatment as usual 
UK United Kingdom 
VAS Visual analogue scale 
WHOQOL-BREF WHO quality of life - BREF 
WP Work package 
WSA Work and Social Adjustment scale 
WTE Whole time equivalent 
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1. BACKGROUND 
EEPRU was approached by Jason Cox (R&D Division) to prepare a programme of research to support 
the appropriateness of, and use of, patient reported outcome measures (PROMs) collected for the 
National Clinical Audit (NCA).  The EEPRU programme was informed by a Research and Development 
(R&D) template prepared by Simon Bennett, Steve Fairman and Keith Willett at NHS England. 
 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the National Health Service (NHS), 2) 
compare the cost-effectiveness of alternative providers in delivering the specific services (i.e. linking 
outcomes and resource use), and 3) assess the cost-effectiveness of alternative interventions and 
other changes in the NHS.  The intention is to introduce PROMs across a range of conditions over the 
next 3 years commencing with 13 conditions in the 2014/15 NCA programme.  
 
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the DH (8
th
 November 2013).  The current document provides details on the 
objectives, methodology and results for Work Package 1 (WP1): to determine what PROMS should 
be used in the 13 health conditions specified in the 2014/15 NCA programme. 
 
2. OVERVIEW 
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the Euro-QoL 5 dimensions (EQ-5D) is appropriate in the 13 health 
conditions specified in the 2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
 
Each component consists of a series of reviews of the literature. 
 
This Appendix provides the detailed results for recipients of psychological therapies and should be 
read in conjunction with both the main report and the methods/search strategy appendices. 
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3. METHOD 
The full detailed methodology used is provided in Appendix A, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, a review of the literature 
was undertaken to assess the appropriateness of the EQ-5D in terms of classic psychometric criteria 
(WP1.1); where the EQ-5D was not considered appropriate, additional searches were undertaken to 
identify alternative measures (WP1.2); and finally, existing health technology appraisals (HTAs) were 
reviewed and data requirements were compared with variables currently collected in the 
psychological therapy audit (WP1.3).   
 
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to using an alternative condition specific or 
generic measure). In case b) the measure may be completed by multiple people (proxies) on the 
ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂůĨ ĂŶĚ ƚŚĞŝƌ ƌĞƐƉŽŶƐĞƐ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚŽƐĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ? tŚĞƌĞ ƚŚĞ ŽƵƚĐŽŵĞ
measure is specifically designed for self-report by patients, this test of reliability may be expected to 
produce less agreement.  
 
Construct validity 
This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
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a) Known group validity, where estimates for groups that are known to differ in a concept of interest 
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the 
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
 
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can 
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
and standardised response mean were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of 
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
 
3.2 Alternative measures (WP1.2) 
Searches were conducted to identify exsting reports and guidelines relating to other measures that 
could be used in depression and anxiety. The results of WP1.1 suggested that the EQ-5D was 
appropriate for depression, with less certainty about its use in patients with anxiety. WP1.2 
therefore concentrated on other measures for anxiety.  
 
3.3 Evidence required for economic evaluations (WP1.3) 
The existing health technology assessments (HTAs) were reviewed alongside the variables currently 
collected in the NCA to determine if clinical or PROM data routinely collected in the NCAs would 
suffice to address questions of cost-effectiveness, and to identify any gaps in the evidence that 
would be required to compare providers, or the cost-effectiveness of interventions or policies. 
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4. RESULTS FOR PSYCHOLOGICAL THERAPIES 
4.1 Evidence of appropriateness of EQ-5D in psychological therapies (WP1.1) 
4.1.1 Selection of systematic review 
Two systematic reviews were identified through expert sources.(1),(2) The process of selection of 
the most appropriate review is documented in Table 1. Peasgood et al. was selected as it provides 
more detail about the psychometric properties of the EQ-5D, and is more recent than the Oxford 
review.(2) 
 
Table 1: Selection of most appropriate review for psychological therapies  
Review Search date Relevance of 
review 
Quality of search Quality of 
review 
Selection 
Oxford review 
(2) 
Unclear Question 
relevant, but 
too little 
psychometric 
data provided 
Reliance on pre-
existing 
database, with 
additional 
searches, but full 
strategy not 
provided.  
No QA; no 
search 
numbers; other 
methods (DE, 
SS) unclear 
Exclude  W less 
recent than 
Peasgood, less 
psychometric 
detail than 
Peasgood 
      
Peasgood et al. 
2012(1) 
December 2010 Question 
relevant, 
psychometric 
data provided 
Several 
databases 
searched, 
reference lists 
also searched. 
Search strategy 
NR but available 
from authors. 
QA performed; 
search numbers 
provided; DE 
and SS methods 
described (one 
reviewer) 
Include 
QA, quality assessment; DE, data extraction; SS, study selection. 
 
4.1.2 Structured abstract for Peasgood et al.(1) 
Purpose of review 
The review aimed to assess the construct validity and responsiveness of EQ-5D and Short-Form 6 
dimensions (SF-6D) measures in anxiety and depression. 
 
Methods of review 
Search and study selection: Eleven databases were searched. Searches were limited to English 
language. No details of databases searched were provided in the review. Electronic searches were 
conducted in December 2010. The full search strategies were not reported but were available from 
the authors. Reference lists of included papers were hand searched. 
 
Inclusion criteria: Studies were included in the review if they satisfied the following criteria: they 
contained health related quality of life (HRQoL) data as measured by any preference-based health 
10 
 
measure for adults with depression or anxiety. Study design could include controlled trials or studies 
examining the burden of illness in depression or anxiety. Studies had to contain data from the 
HRQoL instrument that allowed measurement of construct validity (convergent or known groups), or 
responsiveness of the measure.  
 
Exclusion criteria: Studies were excluded from the review if the study population did not have a 
primary diagnosis of depression, i.e. it was comorbid to another condition. Studies that only 
contained data relating to the visual analogue scale of the EQ-5D were excluded. 
 
Data extraction and synthesis: Data were extracted by one reviewer using a newly developed form, 
designed for specific use in a wider review. Due to heterogeneity between studies, a narrative 
synthesis was performed and data tabulated according to the psychometric quality assessed, namely 
construct validity and responsiveness. These were defined by the review authors as follows: 
Construct validity, the degree to which an instrument measures the construct it is designed to 
measure and in the settings it is designed to measure. This can be measured by one of two methods. 
Known or extreme groups: where in two groups who differ in a trait or behaviour , one group is 
expected to score significantly higher or lower compared with the other group (definition from 
Streiner 2003);(3) Convergent validity: where the relationship between two instruments measuring 
ƚŚĞ ƐĂŵĞ ĐŽŶƐƚƌƵĐƚ ŝƐ ĂƐƐĞƐƐĞĚ ďǇ WĞĂƌƐŽŶ ?Ɛ ƉƌŽĚƵĐƚ ŵŽǀĞŵĞŶƚ ĐŽƌƌĞůĂƚŝŽŶ Žƌ ^ƉĞĂƌŵĂŶ ?Ɛ ƌĂŶŬ
correlation. Secondly, responsiveness was defined as the extent to which an instrument can detect a 
clinically significant or practically important change over time (definition from Walters 2009).(4) 
Effect sizes for responsiveness were most commonly calculated using the standardised response 
mean (SRM) Žƌ ŽŚĞŶ ?Ɛ  ƐƚĂƚŝƐƚŝĐ ? ĨĨĞĐƚ ƐŝǌĞ ƚŚƌĞƐŚŽůĚƐ ĨŽƌ ŽŚĞŶ ?Ɛ  ǁĞƌĞ P  ? ? ? ǁĂs defined as 
small, 0.5 was defined as moderate, and 0.8 was defined as large. 
 
Results of the review   
A total of 26 studies were identified that provided data relating to the construct validity or 
responsiveness of the EQ-5D or the SF-36. 21 of these studies evaluated the construct validity or 
responsiveness of the EQ-5D. The remaining studies did not report data relating to the construct 
validity or responsiveness of the EQ-5D and therefore do not meet the inclusion criteria of WP 1.1 
and will not be discussed here.  
 
Studies were conducted in a wide range of countries. One study used the German EQ-5D,(5) and one 
used the UK EQ-5D 15D measure with Finnish valuations.(6)  Whilst several of the remaining studies 
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specified use of the EQ-5D UK, no further details of which version of the EQ-5D are provided for 
many studies, it is therefore unclear whether the UK version was used. Five studies were conducted 
in the UK.(7-11)  Three studies were multinational(12-14), one was conducted in France(15); two in 
Germany(16;17); three in the Netherlands(18-20); one in Canada(21); one in Sweden(22), two in 
Turkey(23;24), and one in the USA(25). 
 
A range of measures were used to assess the construct validity and/or responsiveness of the EQ-5D. 
Measures used for comparison included symptom measures such as: Center for epidemiologic 
studies  W depression (CES-D)(20); Hamilton depression rating scale (HAM-D) (23;24); Beck anxiety 
inventory (BAI)(11;16;17); Beck depression inventory (BDI)(9;11;16;17); Hamilton anxiety rating scale 
(HAM-A)(25); Patient health questionnaire - depression (PHQ-D)(7;16); Montgomery-Asberg 
depression rating scale (MADRS)(13;15;18); hospital anxiety and depression scale (depression) 
HADS-D(10;12;14;20); hospital anxiety and depression scale (anxiety) (HADS-A)(12;14); Edinburgh 
postnatal depression scale (EPDS)(8). Functional measures were also used as comparators: Clinical 
global impression scale  W severity (CGI-S)(5;15;22), and global assessment of functioning (GAF)(5). 
Other generic quality of life measures were also included: World Health Organisation quality of life  W 
bref (WHOQOL-BREF)(5), Bech-Rafaelsen melancholia scale (BRAMES)(5), quality of life in depression 
scale (QLDS)(13;15), and short form  W 36 (SF-36)(7;10;19) and short form  W 6 dimensions (SF-
6D)(8;14;15).  
 
Population characteristics differed across studies. Mean ages ranged from 39.6 years(23) to 74.1 
years.(11)  Ten studies focused on individuals with depression(5;9;10;12-15;18;23;24), 3 studies 
focused on individuals with anxiety(16;17;25), 3 focused on individuals with either depression or 
anxiety(6;19;20). The remaining 2 studies were surveys of the general population, aiming to identify 
individuals with postnatal depression(8) or depression or anxiety(21). The number of withdrawals 
was not reported.  
 
Study designs were not always reported. Where reported, most studies consisted of controlled 
trials.(7-11;13;16-18;24;25) Four studies were population surveys.(6;15;21;22)   
 
Construct validity (known group): Ten studies reported data on construct validity using the known-
groups method.(6-8;14;15;17;19;21-23;25) Patients were grouped by disease severity(7;15;17;25), 
single/recurrent depression groups(23), symptom checklist (SCL) subgroups(19), or self-report health 
status group. (8)  Most studies found that the EQ-5D was able to distinguish between groups, 
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although Aydemir et al. found no significant differences between individuals having a single episode 
compared to those having recurrent depressive episodes, with effect sizes of 0.45 and 0.41 
respectively. (23)  Saarni et al. showed that the EQ-5D was able to distinguish between depression 
and anxiety disorders, with lower EQ-5D scores for people with depression (-0.091 lower than the 
general population), anxiety (-0.114 lower), generalised anxiety disorder (GAD) (-0.110 lower), major 
depressive disorder (MDD) (-0.058 lower), dysthymia (-0.122 lower), and social phobia (-0.102 
lower). No significant differenences were found for panic disorder or agoraphobia.(6) Supina et al. 
also showed that the EQ-5D could distinguish between groups of patients with anxiety or 
depression, with mean EQ-5D scores for individuals with major depressive episode (MDE) of 0.83, 
scores for individuals with anxiety 0.84, scores for individuals with both conditions reducing to 0.70, 
compared with 0.92 for individuals with neither condition. The EQ-5D was also shown to distinguish 
between groups by severity of depression.(21) Sobocki et al. reported mean EQ-5D scores of 0.60 for 
mild depression, 0.46 for moderate depression, and 0.27 for those with severe depression, as 
assessed by CGI-S.(22)  Konig et al. compared the mean BAI scores for groups who indicated they 
had a problem on the EQ-5D anxiety/depression health dimension with those who had no problem. 
They found that most of the EQ-5D dimension response levels (especially for anxiety and depression) 
were associated with significant differences in scores of WHOQoL and measures of psychopathology 
such as BAI scores.(17) Mann 2009 showed that EQ-5D distinguished between depression severity 
groups, with mean scores of 0.645 for mild depression, 0.656 for moderate, 0.558 for 
moderate/severe, and 0.337 for severe.(7)  Mycheski et al. also showed decreases in EQ-5D scores 
by severity group, this time for anxiety, with mean EQ-5D scores reducing with increasing anxiety 
severity (normal 0.83, mild 0.78, moderate 0.60, severe 0.30).(25)  Petrou 2009 also showed that 
EQ-5D scores decreased in line with self-reported health status, although the SF-36 was found to be 
more efficient  ?ĚĞƐĐƌŝďĞĚ ŝŶ WĞĂƐŐŽŽĚ ĂƐ  “Relative efficiency statistic  W how well can they detect 
differences in self reported (SR) health status and EPDS. Ratio of the square of the t-statistic of the 
comparator ŝŶƐƚƌƵŵĞŶƚŽǀĞƌƚŚĞƐƋƵĂƌĞŽĨƚŚĞƚƐƚĂƚŝƐƚŝĐŽĨƚŚĞƌĞĨĞƌĞŶĐĞŝŶƐƚƌƵŵĞŶƚ ? ? ?.(8) 
 
Construct validity (convergent):  Five studies tested the convergent validity of the EQ-5D compared 
to a variety of other measures (Ayedemir 2009, Gunther 2008, Konig 2010, Mann 2009, Sapin 2004).  
Correlations with symptom measures showed differences between studies in the strength of these 
relationships, ranging from not significant for the body sensation questionnaire (BSQ), agoraphobic 
cognitions questionnaire (ACQ), mobility inventory  W avoidance alone (MIA), mobility inventory  W 
avoidance accompanied (MIB) (17), to very strong (-0.77) on HAM-D,(23) and 0.7 on physical health 
WHO-QOL (17). Moderate correlations were found between EQ-5D and functional measures (r=0.49 
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with GAF, -0.58 with BRAMES)(5)  For symptom measures, Konig 2010 showed significant 
correlations with BAI (r=-0.58) and BDI-II (r=-0.54).(17)  A significant correlation was also reported 
between EQ-5D and other generic quality of health measures, with Sapin 2004 finding moderate to 
strong correlations between EQ-5D and SF-36 (0.49 at baseline, increasing to 0.63 at day 56). (15)  
Finally, Mann 2009 showed significant correlations between EQ-5D and PHQ-9, increasing from -
0.451 at baseline to -0.638 at 3 month follow-up. (7) 
 
Responsiveness (change over time): Sixteen studies assessed responsiveness through changes in 
EQ-5D scores over time (table A6).  Significant responsiveness was found for studies of depression. 
Fernandez 2005 showed responsiveness to improvement after treatment from baseline to 8 week 
follow-up, with mean differences in EQ-5D scores for patients with severe MDD on escitalopram 
0.52 to 0.78 (p<0.001), and those on venlaxafine 0.54 to 0.77 (p<0.001).(13) Gunther 2008 
demonstrated responsiveness of the EQ-5D to deterioration over time. EQ-5D scores were found to 
deteriorate for those in the worst health (-0.290) more than they improved for those in better health 
(0.155).(5)  Mann 2009 showed in an RCT of collaborative care for major depressive disorder that the 
EQ-5D was responsive over time, with scores increasing by 0.147 between baseline and follow-up at 
3 months.(7) Sapin 2004 demonstrated responsiveness to improvement in anxiety/depression over 
time. EQ-5D scores showed improvement of 0.35 at 4 weeks and 0.45 at 8 weeks. After 8 weeks, 
9.3% of individuals reported extreme problems with anxiety / depression, compared with 77.9% at 
baseline. EQ-5D was also able to distinguish responder-remitters, responder non-remitters and non-
responders based on MADRS score.(15) Caruso 2010 also showed that EQ-5D was responsive over 
time for individuals with depression, with mean scores improving from 0.40 at baseline to 0.66 
(0.73) at 3 (6) months.(12)  Swan 2004 showed responsiveness of the EQ-5D in patients with 
depression following a Coping with Depression course, with scores increasing from 0.49 at baseline, 
to 0.65 (0.68) at week 12 (26). These improvements aligned with scores on the GSI and BDI.(9)  Van 
Straten 2008 found significant responsiveness for EQ-5D in patients with depression taking part in a 
trial of a web-based self-help intervention. Using post-intervention improvement scores for those 
ǁŚŽĐŽŵƉůĞƚĞĚƚŚĞĐŽƵƌƐĞĂƐƚŚĞŝƌŽƵƚĐŽŵĞŵĞĂƐƵƌĞ ?ƚŚĞĂƵƚŚŽƌƐƌĞƉŽƌƚĞĨĨĞĐƚƐŝǌĞƐ ?ŽŚĞŶ ?Ɛ ?ŽĨ
EQ-5D (ES=0.31), compared to CES-D (ES=0.5), MID (ES=0.33) and SCL-A (ES=0.42). (20)   
 
Bosmans et al. showed no significant difference in quality adjusted life years (QALYs) gained 
between antidepressant and usual care control groups (standardised mean difference (SMD) -
0.00045), although nor was there a significant difference in improvement on the MADRS score (SMD 
-0.81).(18)  Peveler et al. reported a numerical change from baseline for each of three treatment 
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groups for improvement in depression symptoms at 12 months (10). Peasgood et al. report that 
whilst mean scores for all groups showed improvement, this was non-significant because of high 
standard deviation (Peasgood).  Serfaty et al. failed to find significant responsiveness of EQ-5D in 
patients with depression taking part in an RCT of CBT versus treatment as usual (TAU). Mean EQ-5D 
scores remained similar from baseline (0.50), at 4 months (0.53) and 10 months (0.54) for those in 
the CBT group, and baseline (0.52), 4 months (0.55) and 10 months (0.52) for those receiving TAU. 
The findings of Serfaty et al. are an exception to the general picture of responsiveness of the EQ-5D. 
In this study, the EQ-5D was less responsiveness than the BDI-II. A possible explanation is that EQ-5D 
may lack responsiveness for older patients, as the patient group in this study had a mean age of 74.1 
years.(11)  For individuals with anxiety, although Konig et al. 2009 found no significant difference for 
the EQ-5D between intervention and control groups in a trial of training versus treatment as usual 
(TAU), scores on the BDI and BAI did not detect any differences either.(16) However for the same 
sample, Konig et al. 2010 reported effect sizes for anxiety by severity group. Results showed effect 
sizes for the EQ-5D (ES=- ? ? ? ? ?ĨŽƌ ?ŵŽƌĞĂŶǆŝĞƚǇ ? ?ǁĂƐƚǁŝĐĞĂƐůĂƌŐĞĂƐĨŽƌƚŚĞĐŽŵƉĂƌĂƚŽƌ measures 
(WHOQoL, BSQ ACQ), and the corresponding SRM (SRM=-0.54) was also more responsive than the 
other measures, suggesting the EQ-5D may overestimate improvements(17)  Mychawski et al. also 
demonstrated the responsiveness of the EQ-5D between those in functional remission from anxiety 
and those not in remission (mean EQ-5D: 0.87 vs. 0.61 at 8 week follow-up).(25)   Finally, Lamers et 
al. showed the EQ-5D was responsive over 1.5 years follow-up in a group of patients with anxiety, 
with EQ-5D scores increasing from 0.513 to 0.680, compared to the SF-6D, where scores increased 
over time from 0.577 to 0.701.(19) 
 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ: See Section 4.1.4 below. 
 
4.1.3 Assessment of the review in relation to objectives of work package 1.1 
Relevance of review question: The aim of Peasgood et al 2011(1) is convergent with the aims of 
WP1.1.  
 
Assessment of review quality:  Assessment of the quality of the review was conducted using a 
modified version of the AMSTAR tool (Shea et al 2007) and also by considering the strength and 
quantity of the evidence. The adequacy of the reported data in the context of work package 1.1 was 
also assessed.  A summary of the quality assessment is shown in the Appendix. 
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Peasgood et al. 2011(1) scored well against most of the relevant AMSTAR criteria. Reference is made 
to a published protocol to evidence an a priori design, thus reducing the possibility of changes to the 
protocol in response to results. Quality assessment of the included studies was conducted and whilst 
no formal method for assessing the quality of this type of study has been previously validated, 
methods published elsewhere were followed.(2)  Study selection was carried out by only one 
reviewer, and double data extraction or data-checking was not conducted, leaving the study at 
higher risk of errors. Inclusion/exclusion criteria are clearly defined. 
 
Acceptability of the search:  A comprehensive search of a wide range of sources was carried out 
including reference tracking.  
 
Acceptability of study selection: Study selection criteria were clearly defined. 
 
Adequacy of available data and synthesis:  The review only provided a small amount of data relating 
to each study, however this was adequate for the purposes of WP 1.1.  
 
4.1.4 Conclusion of appropriateness of EQ-5D for psychological therapies (anxiety and depression) 
The authors concluded that while the evidence base supports the use of the EQ-5D in patients with 
anxiety and depression, there is evidence to suggest the EQ-5D may lack responsiveness in the 
elderly.(1)  They also noted a stronger correlation with depression scales than anxiety scales in 
patients with anxiety which suggests the known group validity results may be driven by the presence 
of comorbid depression or the depression aspect within anxiety disorders.   Comparing the results of 
the EQ-5D with the SF-6D, as has been found elsewhere,(26) the authors noted that the EQ-5D 
showed greater improvements than the SF-6D for those at the lower end of the HRQoL spectrum 
(e.g. severe depression) while the SF-6D appeared to be more sensitive to changes at the top end of 
the HRQoL spectrum (e.g. mild depression).   
 
The evidence suggests the EQ-5D is appropriate in patients with depression, but additional research 
is required to confirm its appropriateness in patients with anxiety conditions.  
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Table 2: Summary of evidence on EQ-5D for patients receiving psychological therapies 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Adults 
EQ-5D (21) Not reported   Not 
reported            
Good; Good Mixed; not reported 
 Authors note that EQ-5D correlations were higher when compared against depression than anxiety 
scales in patients with anxiety (study n=1), that there may be a lack of responsiveness in older 
adults (study n=1) and that the EQ-5D showed greater changes at the lower end of the HRQoL 
spectrum.  
The EQ-5D is appropriate in patients with depression, but additional research is needed to confirm 
its appropriateness in patients with anxiety.  
EQ-5D: EuroQol 5 dimensions; HRQoL: health related quality of life. 
 
4.2 Alternative measures in psychological therapies (WP1.2) 
Evidence from WP1.1 for psychological therapies suggests that the EQ-5D is appropriate for use in 
depression, though there may be a lack of responsiveness in older adults, and additional research is 
needed to confirm its appropriateness in patients with anxiety. Both the latter conclusions were 
based on single studies.(11;17) 
 
To investigate other measures that may be appropriate for use in psychological therapies, searches 
for WP1.2 were conducted and six reports of potential relevance were identified. Characteristics and 
recommendations of these reports are given in the Appendix. One was a report to the DH from the 
Oxford PROMS group,(2) and had similar aims to WP1.2. Two reports were from the Royal College of 
Psychiatrists with the aim of providing recommendations to clinicians. Both covered several mental 
health topics; one concentrated on adults and one on older adults. The report for older adults was 
intended to aid the improvement of care and the assessment of individual patient outcomes. The 
three remaining reports were research recommendations from the EMA, and were intended as 
recommendations for clinical research into interventions for anxiety in consideration of a submission 
to the EMA for licensing in Europe. Each covered a different anxiety condition, namely: generalised 
anxiety disorder (GAD); panic disorder; and social anxiety disorder. These latter three reports were 
deemed too specific in their topics to be useful in an audit context where a wide range of anxiety 
disorders would be encountered, and were not considered further.   
 
Only the Oxford PROMS group review(2) had the same aim as WP1.2, with most others 
recommending measures for use in clinical practice or clinical research. With the exception of the 
Oxford review, none reported robust methods of assessment which included evaluation of 
psychometric evidence; the majority used an expert panel or working group to conclude which if any 
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measure was suitable in the specific conditions. None of the reviews aimed to provide a 
comprehensive list of validated measures.  
 
The most relevant report for WP1.2 came from the Oxford PROMS group.(2) This report did not, 
however, come up with one single recommendation and did not consider all measures available. It 
concluded ƚŚĂƚ  “ŽŵƉĂƌĞĚ ƚŽ ƚŚĞ ĚĞďĂƚĞƐ ĂďŽƵƚ ƐĐƌĞĞŶŝŶŐ ĂŶĚ ƵƐĞ ŝŶ ƚŚĞ ĐŽŶƚĞǆƚ ŽĨ ŝŶĚŝǀŝĚƵĂů
patient care, the debate about PROMs and quality in mental health services is still in its earliest 
ƐƚĂŐĞƐ ? ?(2)   Of most relevance to WP1.2 were ƚŚĞƌĞƉŽƌƚ ?ƐĐŽŶƐŝĚĞƌĂƚŝŽŶƐĂďŽƵƚĐŚŽŽƐŝŶŐĂŵĞĂƐƵƌĞ
that covers both anxiety and depression, for which Clinical Outcomes in Routine Evaluation  ?  
Outcome Measure (CORE-OM) was preferred over HADS, as it had a better level of evidence to 
support it and included social function. The report stated that if a preference measure is required, 
EQ-5D is preferred over the SF-6D.  
 
For adult populations, the Royal College of Psychiatrists give as examples the patient health 
questionnaire (PHQ-9), a 9-item depression scale intended to diagnose and monitor depression; the 
Generalised Anxiety Disorder Assessment -7 (GAD-7), a seven-item questionnaire used as a 
screening tool and severity measure for generalised anxiety disorder; CORE-OM, used before and 
after therapy; and also recommends both the EQ-5D and the SF-6D. In older adults, the Royal 
College recommends GAD-7 and the hospital anxiety and depression scale (HADS), but notes that 
the latter may miss somatic symptoms.  
 
It is also worth noting that a new measure is in development that is intended to be suitable for use 
across the spectrum of psychotic and non-psychotic mental health conditions.(Department of Health 
2013) The measure, Recovering Quality of Life (ReQoL) is currently under development by the Policy 
Research Unit in Economic Evaluation of Health and Care Interventions and is due to be available 
around July 2015.(27)  Once the measure is available and has been validated in people with 
depression and anxiety, the ReQoL may become a candidate measure for inclusion in the NCA. 
 
 
4.3 Evidence for economic evaluations in psychological therapies (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in psychological therapies 
Just one multiple technology appraisal (MTA) in psychological therapies for depression and anxiety 
(published in 2002) was identified from the searches.(28)  This was superseded by a later TA,(29) 
which was subsequently withdrawn, leaving no valid TAs for this condition.  As a consequence the 
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most recent CG in anxiety and depression was identified.(30)  The CG encompassed a broad decision 
space covering pharmacological and physical interventions, services (organisation of care, 
development of staff roles, introduction of mental health specialists into primary care), and 
psychological and psychosocial interventions.  The following text reviews the economic evidence 
relating to psychological therapies only (i.e. Sections 6 to 8 of the CG).  The guideline team identified 
two studies describing economic evaluations for (low-intensity psychological interventions),(28;31) 
and two studies describing economic evaluations for (high-intensity psychological 
interventions).(32;33) 
 
The low-intensity studies both evaluated CCBT software packages (Beating the Blues (31;34), 
Overcoming Depression and Cope(34)) compared to standard care in patients with depression in the 
UK (Table 3).  McCrone conducted an economic evaluation alongside a clinical trial. The main results 
were reported in terms of cost per point reduction in Becks Depression Index (BDI).(35;36)  Although 
they also reported a cost-utility evaluation, the methodology used to weight the survival for the 
QALYs was not considered to be robust.(34)  Kaltenthaler et al. used a decision tree to compare the 
interventions under evaluation.  The clinical pathway was described using discrete health states 
based on severity of depression (Figure 1) using well-established cut-offs relating to the BDI: minimal 
 ?ч ? ? ?ŵŝůĚ ? ? ?-18), moderate (19-29), and severe (30-63). The intervention specific severity evidence 
(i.e. the proportion in each severity category whilst on treatment) was sourced from clinical trials 
and the rate of relapse (assumed equivalent for both interventions) was sourced from the literature. 
Mean EQ-5D scores were assigned to the discrete health states within the model.  The analysts 
reported the relationship between EQ-5D and severity of depression (measured using the BDI 
mapped onto the CORE-OM) was non-linear and rather than using a statistical model to predict 
changes in EQ-5D in the economic model, mean EQ-5D scores were estimated for the individual 
discrete health states. 
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Figure 1: Modelling approach used in psychological therapy HTAs 
 
Legend: Orange framed boxes with uppercase text describe the health states used in the diabetes TA models 
while the purple framed boxes with lower case (plain) text describe the evidence used.  Italised text indicative 
of additional variables which would be informative for future economic evaluations in psychological therapies. 
 
 
One of the two high-intensity studies compared the cost-effectiveness of mindfulness-based 
cognitive therapy (MBCT) compared to maintenance antidepressant medication in people with 
depression.(32)  The second compared cognitive therapy plus antidepressants and clinical 
management with antidepressants and clinical management in people with partially remitted major 
depression.(33)  The primary outcome measure in both studies was cost per relapse or recurrence 
avoided.  Neither study extrapolated beyond the duration of the studies used for effectiveness 
(recurrence/relapse), and neither reported results in terms of cost per QALY.   
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Table 3: Summary of existing models used in psychological therapy TAs 
 Model method, clinical effect  Method used to model utilities  
CG (CG90): Depression in adults, the treatment and management of depression in adults; 2010(30) 
 Did not construct a new evaluation for psychological therapies but identified 2 publications (below) 
describing economic evaluations in this area. 
McCrone, 2003(31) 
 Economic evaluation alongside an RCT, 
generating the cost per point reduction in BDI, 
cost per symptom free day, cost per QALY  
Patient outcomes measured using: Beck 
Depression Inventory (BDI), Beck Anxiety 
Inventory (BAI), Work and Social Adjustment 
Scale (WSA) 
Effectiveness: depression free days per 
intervention  
Source: RCT evidence 
Utility: measure not reported; applied to days with 
and without symptoms of depression 
Source: published literature synthesis a variety of 
different measures 
AEs: not applicable 
Kaltenthaler, 2008(34) 
 Decision tree model 
Discrete health states: minimal, mild, moderate, 
severe depression , relapse vs. non-relapse 
Effectiveness: rates for depression severity   
Source: RCTs used for clinical effect 
Utility: EQ-5D; mean values assigned to discrete HS 
based on a relationship between the BDI and the 
CORE-OM 
Source: published literature showing a relationship 
between clinical severity (CORE-OM) and EQ-5D 
scores 
AEs: not applicable 
HS: health states; AE: Adverse Events; CG: Clinical Guideline; RCT: randomised controlled trial 
 
 
In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for psychological therapies: 
 
x Screening for anxiety / depression  
x Information on physical comorbidities  
x Intervention  
x Compliance to intervention/completion rates 
x Condition specific PROM (such as BDI, BAI) 
x Severity measure (using validated measure for mild, moderate or severe) 
x Recurrence/relapse rates (with dates) 
x Utility values 
 
The majority of this evidence would need to be dated and linked through timings of collection.  
Although the models reviewed applied utility values to discrete health states, with more detailed 
information from a large dataset, the association between depression and HRQoL could potentially 
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be measured as a continuous relationship using a similar approach to that used in the diabetic vision 
model  (see Appendix E). 
 
 
4.3.2 Fields collected in the psychological therapy NCA  
The National Audit of Psychological Therapies for Anxiety and Depression (NAPT) aims to promote 
access, appropriateness, acceptability and positive outcomes of treatment for people who have 
anxiety or depression.  The audit is open to all NHS-funded services providing psychological 
therapies in the community in England and Wales for people with anxiety or depression. The data 
give a snapshot of information for a designated recall period (e.g. between 1
st
 September and 30
th
 
November 2010) within the audit timescales (Appendix).  The Therapist questionnaire covers areas 
ĚŝƌĞĐƚůǇ ƌĞůĂƚŝŶŐ ƚŽ ƚŚĞ ƚŚĞƌĂƉŝƐƚ ?Ɛ ƚƌĂŝŶŝŶŐ ĂŶĚ ƋƵĂůŝĨŝĐĂƚŝŽŶƐ ĂŶĚ ƚŚĞ ƚǇƉĞ ĂŶĚ ŚŽƵƌƐ ŽĨ ƐĞƌǀŝĐĞ
provided.  The therapist completed retrospective case record questionnaire provides data on 
individual patients (gender, age, date of referral, type of treatment offered and whether taken up/ 
completed, and several outcome measures for example the HADS).  However, the majority of fields 
ŝŶ ƚŚĞƐĞ ƋƵĞƐƚŝŽŶŶĂŝƌĞƐ ĂƌĞ ŽƉƚŝŽŶĂů ? dŚĞƌĞ ĂƉƉĞĂƌƐ ƚŽ ďĞ ĂŶ  ?ŽƵƚĐŽŵĞ ŵĞĂƐƵƌĞ ?  ?ǁŝƚŚŝŶ ƚŚĞ
Retrospective audit section, Appendix), but no detail is provided on what measure is used.  The 
ƐĞƌǀŝĐĞƵƐĞƌ ?ƐƋƵĞƐƚŝŽŶŶĂŝƌĞ ?Talking treatment Survey) is optional and includes information on the 
ƚǇƉĞĂŶĚǀŽůƵŵĞŽĨĐƵƌƌĞŶƚƚƌĞĂƚŵĞŶƚ ?ĂŶĚƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌƐŽŶĂůĞǆƉĞƌŝĞŶĐĞŽĨƚŚĞƚƌĞĂƚŵĞŶƚ ?  The 
questionnaire includes a five item measure (the ARM-5) derived from the full 28 item Agnew 
Relationship Measure (ARM), which was designed to assess the strength of the therapeutic 
relationship between clients and their therapists.(37)    
 
4.3.3 Comparing fields in psychological therapy NCA with variables used in existing HTAs  
The existing models used health states categorised by severity of condition and intervention specific 
relapse rates were used to compare individual therapies.  Responses to the type of psychological 
therapy provided, sub-categorised by high (e.g. cognitive analytic therapy) or low (e.g. psycho 
education) intensity therapy, the number of sessions attended and completion of therapy, are 
mandatory in the retrospective service user questionnaire.  These could potentially be used to 
model adherence and withdrawal rates.  It is not clear if there are currently any fields which could be 
used to model relapse, which is a frequent occurrence in this chronic condition and a key parameter 
for any economic model in this area. 
 
The retrospective service user questionnaire also includes information on initial and final outcome 
scores such as HADs, CORE-10, and BAI which would be useful to measure severity.  While in theory 
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these could be used to identify response to treatment, this would depend on the timings of the data 
collection.  There is evidence in the literature which could be used to link some of these variables to 
preference-based utility values (e.g. HADs to EQ-5D).  However, the functions currently available 
have not been validated on external data and there are issues related to sample sizes and 
representativeness of the clinical severity in the populations used to obtain the functions.  
Consequently it is recommended that the service user questionnaire also includes a measure which 
could be used to generate utilities. 
 
 
4.4 Recommendations for psychological therapies  
The NCA collects information from patients with anxiety or depression receiving psychological 
therapies in the community, and there is a mandatory field (Part D, ICD-10 diagnosis) which could be 
used to differentiate between the subcomponents of this condition.  The Service user questionnaire 
includes a measure to capture the strength of the therapeutic relationship between clients and their 
therapists,(37) and the retrospective service user questionnaire also includes information on 
measures such as the HADs, CORE-10 and BAI.  However, there is no measure which could be used 
to generate preference-based scores directly.  Potential recommendations (PR) and areas for future 
research (FR) are discussed below.  All suggested future research areas are indicative and would 
require a discussion and detailed proposal if required.   
 
It is recommended that the EQ-5D is collected in the Service user questionnaire alongside clinical 
measures, and that the ReQOL is considered once this becomes available (PR.1, PR.2).  Due to the 
uncertain evidence in patients with anxiety, and the limited evidence in patients with depression, it 
is recommended that additional research is conducted to assess the appropriateness of the measure 
in patients receiving psychological therapies using data collected in the NCA (FR.1). 
 
It is also recommended that therapists use a common set of condition specific measures to capture 
the severity of the condition and response to treatment (for example the PHQ-9 and HAD-7).  To 
facilitate links and comparisons with other sources of data, the measures should be synchronised to 
match measures adopted by the DH for use in the NHS Outcomes Framework (PR.3). 
 
The psychological therapies NCA data is currently being analysed under a separate research project 
(WP3), and the results of this research will inform additional recommendations for the fields in the 
audit (FR.2). 
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Table 4: Recommendations and associated future research for psychological therapies 
PR.1 Collect the EQ-5D in the service user questionnaire alongside clinical measures such as the 
PHQ-9 and GAD-7 
PR.2 Collect the ReQOL in the service user questionnaire once it becomes available 
FR.1 Assess the appropriateness of the EQ-5D and the ReQoL in patients receiving psychological 
therapies using the data from the NCA 
PR.3 All therapists use a common set of measures (to be decided and ultimately synchronised 
with the measure adopted for use in NHS Outcome Framework) 
PR.4 Include additional mandatory fields in the psychological therapies NCA 
FR.2 Detailed analyses of fields collected in the current NCA is being undertaken under a 
separate research project within this programme of work (WP.3).   
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5. SUMMARY 
5.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
An existing review provided evidence from 21 primary studies relating to the EQ-5D in psychological 
therapies (Table 5). Construct validity (both known group and convergent) was reported to be good, 
though data from one study showed that the EQ-5D correlated better with depression-specific 
measures and subscales than with anxiety-specific ones in people with anxiety. This suggests that 
additional research is required to confirm the appropriateness of the EQ-5D in patients with anxiety. 
Responsiveness was more mixed, but generally good, though notably one study in the elderly 
showed poor responsiveness. Better responsiveness of the EQ-5D was observed at the lower end of 
the HRQoL spectrum (e.g. severe depression) when compared to the SF-6D, which was more 
sensitive to changes at the top end of the spectrum. Overall, the EQ-5D was considered appropriate 
for use in anxiety and depression, though further validation work is required in anxiety. Searches 
were conducted to identify other measures. In keeping with The Royal College of Psychiatry, the 
GAD-7 and PHQ-9 measures are recommended for use alongside the EQ-5D. ReQoL, a measure 
currently in development by EEPRU for use in psychotic and non-psychotic mental health conditions 
is due to be available in July 2015, and could be considered for use once available.  
 
Table 5: Summary of evidence currently available for recommended measure(s) 
Measure N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change  
over 
time 
Ceiling  
Effect 
EQ-5D  21 NR NR Good Good Mixed NR Acceptable 
PHQ-9  Recommended by the Royal College of Psychiatrists 
GAD-7  Recommended by the Royal College of Psychiatrists 
ReQOL  This measure is currently in development and will be available in 2015 
N= number of studies used to inform conclusions, KGV: known group validity; NR, the existing review did not 
review this psychometric property 
 
5.2 Summary of evidence required for use in economic evaluations (WP1.3) 
Although the audit for patients receiving psychological therapies does not collect PROMs, there is a 
service user questionnaire which could potentially be amended to include a PROM.  Two measures 
 ?ƚŚĞĞĐŬ ?ƐĚĞƉƌĞƐƐŝŽŶ ŝŶĚĞǆ ?ĂŶĚƚŚĞĞĐŬ ?s anxiety index) are also collected in the audit and it is 
possible that this evidence could be used to predict preference-based utility data using existing 
ƉƵďůŝƐŚĞĚ ƌĞůĂƚŝŽŶƐŚŝƉƐ ? dŚĞƌĞ ĂůƐŽ ĂƉƉĞĂƌƐ ƚŽ ďĞ ĂŶ  ?ŽƵƚĐŽŵĞŵĞĂƐƵƌĞ ?ǁŝƚŚŝŶ ƚŚĞ ƌĞƚƌŽƐƉĞĐƚŝǀĞ
audit but it is unclear what this measure is hence it is not possible to determine its usefulness.  
Relapse rates are high for this condition and compliance to therapy can be problematic.  Together 
with severity of the condition, these are key variables within economic evaluations but it is not clear 
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if there are currently any mandatory fields within the audit relating to these.  This audit is currently 
being used as a case-study in an associated project (WP3), and the results of this project will provide 
an indication of what can be achieved with the data collected. 
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APPENDIX: PSYCHOLOGICAL THERAPIES 
The tables in this Appendix provide additional information for the reviews (WP1.1, 1.2 and 1.3) conducted for 
psychological therapies.  
 
Table A1: Quality assessment for Peasgood et al (Psychological therapies)(1) 
Quality assessment criteria Compliance with criteria 
AMSTAR  
Was an a priori design provided? Yes 
Was there duplicate study selection and data 
extraction? 
No 
Were the methods used to combine the findings of 
the studies appropriate? 
Yes, narrative synthesis due to heterogeneity. 
Was the scientific quality of the included studies 
assessed and documented? 
Yes, using method described in Fitzsimmons et al., 
only for items relating to utility measures 
Was the scientific quality of the included studies used 
appropriately in formulating conclusions? 
Yes 
Overall judgement of quality of review Good but only 1 reviewer. 
Quality of the searches  Acceptable 
Strength of the evidence  
Were the conclusions robust and conclusive? Yes for depression, mixed for anxiety 
Quantity of the evidence  
Was there enough data to be confident that any 
additional data published subsequently would be very 
unlikely to change the conclusions drawn? 
Yes 
Adequacy of data reported  
Did the review provide sufficient data to allow 
integration of an update/assessment of the methods 
used? 
Yes 
Did the review assess EQ-5D in a way compatible with 
the aims of work package 1.1? 
Yes, construct validity (known groups or convergent) 
or responsiveness (effect sizes, standardised response 
means, or correlation with change scores on 
symptom measures). 
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Table A2: Characteristics of primary studies included in Peasgood review for psychological therapies. Adapted from Peasgood et al.(1) 
Author, year Study design Condition Study information Male/female Mean age at 
baseline 
Aydemir et al, 2009, 
Turkey(23) 
RCT  W no further information Major depressive episode according to 
DSM-IV criteria 
N=74 36.5%/63.5% Mean age 39.6 
years 
Bosmans et al., 2008, 
The Netherlands(18) 
RCT: 2 x intervention groups: 
 
Usual care no AD 
Usual care plus AD 
Major or mild-major depression in 
primary care 
N=89 27%/73% Mean age 48 
Caruso et al., 2010, 
Multinational(12) 
Cross-sectional 
FINDER study 
Clinically diagnosed episode of 
depression requiring pharmacological 
treatment 
N=513 16.1%/72.9% Mean age 49.2 
years 
Ergun, (no year), 
Turkey(24) 
RCT  W no further information Major depressive disorder N=74 N/R but is same 
study as Aydemir 
2009 
N/R but is same 
study as Aydemir 
2009 
Fernandez et al., 2005, 
multinational(13) 
RCT of Escitalopram vs venlafaxine DSM-IV criteria for severe major 
depressive disorder 
N=293 Escitalopram 
24.6%/75.4% 
Venlafaxine 
28.8%/71.2% 
Escitalopram 
mean age 48.4 
years 
Venlafaxine mean 
age 46.5 years 
Gunther et al., 2008, 
Germany(5) 
N/R Patients with a depressive episode 
according to ICD-10 classification 
N/R N/R N/R 
Konig et al., 2009, 
Germany(16) 
Controlled trial. Intervention group 
= training (n=23 GP practices) vs 
control group = usual care (n=23 GP 
practices) 
Patients with anxiety disorder N=389 N/R N/R 
Konig et al., 2010, 
Germany(17) 
N/R  Anxiety disorder N=389  N/R N/R 
Lamers, 2006, 
Netherlands(19) 
N/R Diagnosis of major depressive disorder, 
dysthymic disorder, panic disorder, 
social phobia 
N/R N/R N/R 
Mann et al., 2009, 
UK(7) 
RCT on collaborative care Depression (MDD according to SCID) N=114 23%/77% Mean age 42.5 
years 
Mychaskiw et al., 
2008, USA(25) 
Controlled trial  W treatment with 
pregablin, venlafaxine-XR or 
Non-depressed patients with 
Generalised Anxiety Disorder. 
N=374 N/R N/R 
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Author, year Study design Condition Study information Male/female Mean age at 
baseline 
placebo 
Petrou et al., 2009, 
UK(8) 
RCT. Usual care vs community 
postnatal support visits 
Postnatal women  N=623 (complete 
data for 493)  
100% female Aged 17 and over 
Peveler et al., 2005, 
UK(10) 
RCT. Patients receive TCA, SSRI or 
lofepramine 
Patients with a new depressive episode N=327 32.7%/67.3% Mean age 42.5 
years. 
Reed, 2009, 
multinational(14) 
N/R Patients with clinical depression N=3468 at baseline 
N=2854 data at 
both 3 and 6 month 
follow up 
N/R N/R 
Saarni, 2007, 
Finland(6) 
Population survey Assessment of 12 month prevalence of 
depressive anxiety or alcohol disorders 
(DSM-IV) 
N=5219 N/R N/R 
Sapin, 2004, 
France(15) 
Population survey New episode of major depressive 
disorder (MDD) according to DSM-IV 
N/R N/R N/R 
Serfaty et al., 2009, 
UK(11) 
RCT, CBT vs TAU Older people (aged 65 and over) with 
depression screened by 15-item 
geriatric depression scale or BDI-II score 
14 or more 
N=204 21.6%/79.4% Mean age 74.1 
years 
Sobocki et al., 2007, 
Sweden(22) 
Population survey Diagnosis of depression N=447, baseline 
data n=394 
23%/67% Mean age 47 years 
Van Straten et al., 
2008, Netherlands(20) 
Controlled trial  W web-based self-
help 
Depression, anxiety or work-related 
stress 
N=213 N/R N/R 
Supina et al., 2007, 
Canada(21) 
Population survey Random population sample to identify 
Major Depressive Episode or Anxiety 
disorders 
N=5410 sample size 
N=5,383 successful 
data 
39.8%/61.2% Mean age 40.8 
years 
Swan et al., 2004, 
UK(9) 
Cross-sectional  W patients attending 
Coping with Depression course 
Primary diagnosis of chronic or 
recurrent depressive disorder; current 
depressive episode of at least moderate 
severity 
N=76 entrants, 31 
completed 
intervention 
N/R N/R 
AD: antidepressant; RCT: randomised controlled trial; N/R: not reported; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; MDD: major 
depressive disorder; BDI: Beck depression inventory; CBT: cognitive behavioural therapy; TAU: treatment as usual; TCA: tricyclic antidepressant; SSRI: selective serotonin 
reuptake inhibitor; SCID: structured clinical interview for DSM-IV axis 1 disorders 
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Table A3: Method of assessing validity and responsiveness for individual studies in Peasgood review for psychological therapies. Adapted from Peasgood et al.(1) 
Author, Year, 
Location 
EQ-5D Comparison measure Psychometric 
properties assessed 
Assessment of psychometric properties 
Aydemir et al, 2009, 
Turkey(23) 
EQ-5D UK, EQ-VAS HAM-D, SF-36 Known groups validity, 
convergent validity 
Correlation between EQ-5D and HAM-D 
 
EQ-5D for single/recurrent depression groups 
Bosmans et al., 2008, 
The Netherlands(18) 
EQ-5D UK MADRS Responsiveness Mean difference in QALYs gained between the two intervention 
groups 
Caruso et al., 2010, 
Multinational(12) 
EQ-5D  HADS-D, HADS-A, SSI-28, 
VAS pain 
Responsiveness Regression analysis to explore predictors of EQ-5D 
Ergun, 2007 Turkey 
(linked paper to 
Aydemir 2009)(24) 
EQ-5D UK HAM-D Convergent validity, 
responsiveness 
Correlation with HAM-D, Change in mean from baseline to 6 
weeks follow-up 
Fernandez et al., 
2005, 
multinational(13) 
EQ-5D UK QLDS, MADRAS Responsiveness Change in mean from baseline to week 8 by treatment group 
Gunther et al., 2008, 
Germany(5) 
EQ-5D UK and 
German (based on 
TTO), EQ-5D VAS 
WHOQoL-BREF, CGI-S, GAF, 
BRAMES 
Convergent validity, 
responsiveness 
Spearman rank correlations between EQ-5D and all other 
measures 
 
Change in mean for health severity groups, t statistic, ES & SRM 
Konig et al., 2009, 
Germany(16) 
EQ-5D UK, EQ-VAS PHQ-D, BAI, BDI-II Responsiveness Differences between intervention and control group 
Konig et al., 2010, 
Germany(17) 
EQ-5D UK, EQ-VAS WHO-QoL-BREF, BSQ, ACQ, 
BAI, BDI-II, MI (MIA and 
MIB) 
Known group validity, 
convergent validity, 
responsiveness 
Effect sizes between those with and without anxiety 
 
Correlations between EQ-5D  and other measures 
 
Effect sizes, SRM for anxiety severity 
Lamers, 2006, 
Netherlands(19) 
EQ-5D SF-36 Known group validity, 
responsiveness 
Mean differences for anxiety severity groups 
 
Mean improvement in EQ-5D scores at 1.5 year follow-up, by 
severity groups 
Mann et al., 2009, 
UK(7) 
EQ-5D SCID, PHQ-9, SF-36 Known group validity, 
convergent validity, 
responsiveness 
Correlations between EQ-5D and other measures 
 
EQ-5D scores for depression severity groups 
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Author, Year, 
Location 
EQ-5D Comparison measure Psychometric 
properties assessed 
Assessment of psychometric properties 
Change from baseline scores for EQ-5D and SF-36 
 
Remission rates and MDD rates at follow-up for EQ-5D, SF-36 
Mychaskiw et al., 
2008, USA(25) 
EQ-5D UK HAM-A Known group validity, 
responsiveness 
EQ-5D scores by anxiety severity group 
 
Functional remission at 8 weeks (SDS<5)  
Symptomatic remission (HAM-A score 7) at 8 weeks 
Petrou et al., 2009, 
UK(8) 
EQ-5D SF-6D, EPDS, self-rated 
health status 
Known group validity Change in scores by SR health status group. Relative efficiency 
statistic: how well do they detect differences in SR health status 
and EPDS. Ratio of the square of the t-statistic of the comparator 
instrument over the square of the t statistic of the reference 
instrument 
Peveler et al., 2005, 
UK(10) 
EQ-5D HAD-D, CIS-R, PROQSY, SF-
36 
Responsiveness Improvement from baseline by intervention groups 
Reed, 2009, 
multinational(14) 
EQ-5D, EQ-VAS SF36, HADS-D, HADS-A, SSI-
28-item, Pain VAS 
Known group validity Regression analysis  
Saarni, 2007, 
Finland(6) 
EQ-5D UK, 15D 
measure with 
Finnish valuations. 
M-CICI Known group validity Comparison of individuals with and without psychiatric diagnosis 
Sapin, 2004, 
France(15) 
EQ-5D SF-36, QLDS 
Clinician/physician reported 
MADRS, CGI-S 
Known group validity, 
convergent validity, 
responsiveness 
Differences in EQ-5D by disease severity level/response group. 
Correlation between EQ-5D and other measures. 
Ability to detect differences in mean EQ-5D (and 
Anxiety/Depression health dimension responses) over time, and 
in responders vs. non responders 
Serfaty et al., 2009, 
UK(11) 
EQ-5D (no reference 
to scoring system) 
BDI-II, SFQ Responsiveness Ability to detect differences in mean EQ-5D over time compared 
to changes in BDI-II 
Sobocki et al., 2007, 
Sweden(22) 
EQ-5D UK CGI-S (1-7) (severity), CGI-I 
(Improv.) 
Known group validity 
Responsiveness 
Differences in EQ-5D scores by disease severity as assessed by 
CGI-S.  
EQ-5D score up to 6 months follow-up, and by severity 
Van Straten et al., 
2008, 
Netherlands(20) 
EQ-5D CES-D, MDI, HADS, SCL-A, 
MBI, work-related stress  W 3 
subscales 
Responsiveness EQ-5D for intervention groups pre and post intervention 
ĨĨĞĐƚƐŝǌĞ ?ŽŚĞŶ ?Ɛ ?ĨŽƌĂůůƐĐĂůĞƐ 
Supina et al., 2007, 
Canada(21) 
EQ-5D, EQ-VAS MINI Known group validity EQ-5D scores for anxiety and depression groups 
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Author, Year, 
Location 
EQ-5D Comparison measure Psychometric 
properties assessed 
Assessment of psychometric properties 
Swan et al., 2004, 
UK(9) 
EQ-5D (no reference 
to scoring system) 
BDI-II, BSI which generates 
the GSI 
Responsiveness EQ-5D at baseline, week 12 and week 26. Improvement in BDI 
and GSI (baseline to week 12, baseline to week 26). 
EQ-5D: EuroQoL 5 dimensions; HAM-D: Hamilton depression scale; SF36: short-form 36; MADRS: Montgomery-Asberg depression rating scale; HADS-A: hospital anxiety and 
depression scale - anxiety; HADS-D: hospital anxiety and depression scale - depression; QALYs: quality of life years; SSI-28: somatic symptom inventory; QLDS: quality of life 
in depression scale; WHOQoL-BREF: WHO quality of life - brief; CGI-S: clinical global impression - severity; GAF: global assessment of functioning; TTO: time trade-off; 
BRAMES: Bech-Rafaelsen melancholia scale; ES: effect size; SRM: standardised response mean; BSQ: body shape questionnaire; ACQ: agoraphobic cognitions questionnaire; 
BAI: Beck anxiety inventory; BDI: Beck depression inventory; MI (A&B): mobility inventory, (avoidance alone and accompanied); SCID: structured clinical interview for DSM-
IV axis 1 disorders; PHQ-9: patient health questionnaire; SDS: self-rating depression scale; EPDS: Edinburgh postnatal depression scale; CIS-R: clinical interview schedule - 
revised; PROQSY: a computerised version of the CIS; M-CICI: chronicity coping and impact instrument; SFQ: social functioning questionnaire; CES-D: Center for 
epidemiological studies - depression; MDI: major depression inventory; SCL-A: symptom checklist - anxiety; MBI: Maslach burnout inventory; MINI: mini international 
neuropsychiatric interview; BSI:brief symptom inventory; GSI: global severity index   
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Table A4: Convergent validity results for psychological therapies, adapted from Peasgood et al (1) 
Author, year Method of measuring convergence (e.g. Spearman rank 
correlation, statistical significance) 
Convergent validity results 
Aydemir 
2009(23) 
Correlation between EQ-5D and HAM-D HAM-D correlated with EQ-5D at r=-0.77 
Gunther 
2008(5) 
Spearman rank correlation between EQ-5D and: WHOQoL-BREF, 
CGI-S, GAF, BRAMES 
Significant correlations between EQ-5D and all comparator measures: 
BRAMES: -0.576 
WHO-BREF: 0.545 
CGI: -0.539 
GAF: 0.492 
Konig 
2010(17) 
Correlations between EQ-5D and WHO-QoL-BREF, BSQ, ACQ, 
BAI, BDI-II, MI (MIA and MIB) 
At baseline EQ-5D correlations with other measures: 
Physical health WHO-QoL: 0.7 
Mental health WHO-QoL: 0.5 
Overall WHO-QoL: 0.58 
BAI: -0.58 
BDI-II: -0.54 
BSQ, ACQ, MIA, MIB: all 0.4 and below. 
Mann 
2009(7) 
Correlations between EQ-5D and PHQ-9 EQ-5D correlations with PHQ-9: 
 -0.451 at baseline, -0.638 at 3 month follow-up 
Sapin 
2004(15) 
Correlations between EQ-5D and SF-36, QLDS 
Clinician/physician reported MADRS, CGI-S 
EQ-5D correlations with SF-36 MHC: 
0.49 baseline, 0.56 at day 28, 0.63 at day 56 
EQ-5D: Euro-QoL 5 dimensions; HAM-D: Hamilton depression rating scale; WHOQoL-BREF: WHO quality of life  W brief; CGI-S: clinical global impression scale  W severity; GAF: 
global assessment of functioning; BRAMES: Bech-Rafaelsen melancholia scale; BSQ: body shape questionnaire; ACQ: agoraphobic cognitions questionnaire; BAI: Beck 
anxiety inventory; BDI: Beck depression inventory; MI (A&B): mobility inventory (avoidance alone & accompanied); PHQ-9: patient health questionnaire; SF-36: short-form 
36; QLDS: quality of life in depression scale; MADRS: Montgomery-Asberg depression rating scale 
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Table A5: Known groups results for psychological therapies, adapted from Peasgood et al (1) 
Author, 
year 
Method of measuring known groups validity Known groups validity results 
Aydemir 
2009(23) 
Mean EQ-5D for sub-groups with single vs. recurrent occurrence of 
depression episodes 
EQ-5D:  
Single: 0.45 (SD 0.29)  
Recurrent: 0.41 (SD 0.31) 
(no significant difference, no p-value). 
Konig 
2010(17) 
Compared the mean BAI scores for groups who indicated they had a 
problem on the EQ5D anxiety/depression health dimension with 
those who had no problem  
Most of the EQ-5D dimension response levels (especially anxiety and depression) were 
associated with significant differences in BAI scores 
Lamers 
2006(19) 
Comparing SCL subgroups (no detail on categories reported, 
presumed split by severity of symptoms of anxiety, comparing mean 
EQ-5D for those with more severe anxiety symptoms with those 
with less severe)  
Mean EQ-5D scores showed expected pattern, with a large drop in utility in the most 
severe quartile of the SCL-A list (compared to less severe). The standardised difference 
was smaller in EQ-5D than observed in SF-6D 
Mann 
2009(7) 
EQ-5D scores for depression severity groups 
 
EQ-5D: 
Mild 0.645 (SD 0.23) 
Moderate 0.656 (SD 0.21) 
Moderate severe 0.558 (SD 0.27) 
Severe 0.337 (SD 0.29) 
Mychaski 
2008(25) 
EQ-5D scores for anxiety severity groups EQ-5D scores decreased as anxiety symptom severity increased: 
Normal (HADS 0-7) 0.83 
Mild (HADS 8-10) 0.78 
Moderate (HADS 11-14) 0.60 
Severe (HADS 15-21) 0.30 
Petrou 
2009(8) 
Relative efficiency statistic  W EQ-5D vs SF-6D/EPDS Both EQ-5D and SF-6D show monotonically decreasing scores in line with SR health 
status.  
SF-6D found to be more efficient by 29% to 423.6%. Also more efficient using EPDS 
profiles (between 129.8% and 161.7%). 
Reed 
2009(14) 
Regression analysis Regression analysis found EQ-5D score had significant negative relationship with 
clinical characteristics (number of previous depressive episodes; and duration of 
current episode). Also negatively related to somatic symptoms and VAS pain. 
Saarni 
2007(6) 
Compared mean EQ-5D for sub-groups categorised by conditions 
 
Unadjusted mean EQ-5D scores were: population (0.83); any psychiatric diagnosis 
(0.72).  
Controlling for socio-economic status, somatic comorbidity and psychiatric 
comorbidity: 
Depressive disorders reduced EQ-5D -0.091 (CI -0.114 to 0.068) 
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Anxiety disorders reduced EQ-5D -0.114 (-0.144 to -0.085) 
GAD reduced EQ-5D -0.110 (-0.158 to -0.061) 
MDD -0.058 (-0.079 to -0.036) 
Dysthymia -0.122 (-0.167 to 0.077) 
Panic disorder NS 
Social phobia -0.102 (-0.166 to -0.039) 
Agoraphobia NS 
Sobocki 
2007(22) 
Differences in EQ-5D by disease severity as assessed by CGI-S Significant differences in EQ-5D by disease severity groups as assessed by CGI-S: 
Mild 0.6 (0.54-0.65) 
Moderate 0.46 (0.30-0.48) 
Severe 0.27 (0.21-0.34) 
Supina 
2007(21) 
EQ-5D for mental health diagnosis group EQ-5D: 
Anxiety only (n=601) 0.84 (0.83-0.85) 
MDE only (n=140) 0.83 (0.81-0.85) 
Anxiety and MDE (n=280) 0.70 (0.69-0.72) 
Neither 0.92 (n=4338) (0.91-0.92)  
 EQ-5D: Euro-QoL 5 dimensions; SD: standard deviation; BAI: Beck anxiety inventory; SCL: symptom checklist; SF-6D: short-form 6 dimensions; HADS: hospital anxiety scale; 
EPDS: Edinburgh postnatal depression scale; CI: confidence interval; GAD: generalised anxiety disorder; MDD: major depressive disorder; NS: not significant; CGI-S: clinical 
global impression scale  W severity; MDE: major depressive episode  
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Table A6: Responsiveness results for psychological therapies, adapted from Peasgood et al.(1) 
Author, year Method of measuring responsiveness  Responsiveness results 
Bosmans 
2008(18) 
Mean difference in QALYs gained between the two groups (usual care 
no antidepressants vs usual care plus anti-depressants) 
Mean difference in QALYs gained between the two groups  W 0.00045 (95%CI -
0.093; 0.084) (not significant) 
Difference in improvement in MADRS score -0.81 (95% CI -5.6; 4.0) (not 
significant) 
Ergun(24) Change in mean from baseline to 6 weeks follow-up EQ-5D increase from mean 0.44 to 0.91 at 6 weeks follow-up 
Caruso 
2010(12) 
 Mean differences for intervention group over time EQ-5D: 
Baseline 0.40 (SD 0.01) 
3 month 0.66 (SD 0.26) 
6 month 0.73 (SD 0.23) 
Fernandez 
2005(13) 
Mean differences for intervention groups over time EQ-5D: 
Baseline to week 8 
Escitalopram arm 0.52 to 0.78 (p<0.001) 
Venlaxafine arm 0.54 to 0.77 (p<0.001) 
Gunther 
2008(5) 
Change in mean for health severity groups, t statistic, ES & SRM 3 groups based on those who think health is worse, same or better than at 
baseline. Also 3 group based on BRAMES score. 
EQ-5D (UK) show deterioration for those in worst health (-0.290) larger than the 
improvement for those in better health (0.155) 
For t statistic, ES & SRM: 
EQ-5D t stat, ES and SRM find greater responsiveness to deteriorating health 
(almost twice as large as clinical measures).  
ES for health improvement: CGI most responsive (-0.98 patient-based anchor, -
1.35 clinician-based anchor), VAS (0.84, 1.19), EQ-5D UK (0.55, 0.65). 
Konig 
2009(16) 
Mean differences between intervention (training) and control (usual 
care) group. 
No significant differences between control and intervention group. 
BAI, BDI also showed no significant differences. 
Konig 
2010(17) 
Effect sizes, SRM for all measures by anxiety severity group. EQ-5D, EQ-VAS, WHO-QoL, BSQ, ACQ all show significant differences between 
more anxiety, constant and same (t stat). 
Effect sizes for EQ-5D: 
 -0.99
*
 for more anxiety, 0.39 for less anxiety 
(
*
more than twice that for other measures). 
SRM =-0.54
*
 for more anxiety, 0.46 for less anxiety 
( 
*
EQ-5D higher than other measures: BSQ -0.72, WHO-QoL 0.35). 
Lamers 
2006(19) 
Mean differences for anxiety severity groups Mean EQ-5D utilities increased from 0.513 to 0.680 at 1.5 years, and SF-6D from 
0.577 to 0.701. 
Mean improvement in EQ-5D utilities was lower than for SF-6D in the low 
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severity group and higher for the two subgroups with highest severity.  
Mann 
2009(7) 
Remission rates and MDD rates at follow-up for EQ-5D, SF-36 
 
Change from baseline scores for EQ-5D and SF-36.  
 
Change from baseline EQ-5D increase 0.147 (change in median scores 0.069) 
(significant, no p value reported) 
62% assessed as in remission at follow-up according to SCID.  
Remission at follow-up: mean EQ-5D= 0.759 (SD 0.25), mean SF-6D= 0.707 (SD 
0.12) 
MDD at follow-up: mean EQ-5D=0.506 (0.37), SF-6D 0.550. 
Mean improvement between baseline of overall study population and follow-up 
utility for those with remission was EQ-5D=0.243, SF-6D= 0.140.  
EQ-5D showed larger health gains at follow up for all patients, and for those in 
remission.  
Mychaski 
2008(25) 
Functional remission at 8 weeks (SDS<5)  
Symptomatic remission (HAM-A score 7) at 8 weeks. 
 
Note, this is as categorised (responsiveness) by Peasgood et 
al.[Peasgood 2012] but could be considered as known group validity. 
Those achieving functional remission at 8 weeks (SDS<5): EQ-5D=0.87,  
Those not in remission: EQ-5D=0.61 
Symptomatic remission at 8 weeks: 
HAM-A score 7: remission EQ-5D=0.84, no remission EQ-5D=0.60  
HAM-A score 10: remission EQ-5D=0.83, no remission EQ-5D=0.57 
Peveler 
2005(10) 
Improvement from baseline by intervention groups. EQ-5D of 3 intervention groups showed improvement of about 0.22 points, most 
of which occurred in the first 3 months 
Baseline (n=261) EQ-5D=0.5586 (SD 0.275) 
Month 2 (n=172) EQ-5D=0.763 (SD 0.195) 
Month 12 (n=162) EQ-5D=0.777 (SD 0.194) 
No significant differences between groups. 
Sapin 
2004(15) 
Improvement in EQ-5D score at 4 and 8 week follow-up 4 weeks mean EQ-5D=0.68 (+/- 0.24 range -0.11-1) 
8 weeks mean EQ-5D=0.78 (+/- 0.21 range -0.08 to 1) 
Percentage with extreme difficulties on anxiety & depression was 77.9% at 
baseline and 9.3% at day 56. 
Serfaty 
2009(11) 
Improvement in EQ-5D score and BDI-II score from Baseline to 4 and 
10 week follow-up. 
CBT EQ-5D: 
Baseline: 0.50 (0.32) n=70 
4 months: 0.53 (0.34) n=61 
10 months: 0.54 (0.33) n=56 
 
Taking Control intervention EQ-5D: 
Baseline: 0.52 (0.31) n=67 
4 months: 0.55 (0.39) n=57 
10 months: 0.52 (0.32) n=53 
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Treatment as usual EQ-5D 
Baseline: 0.46 (0.29) n=67 
4 months: 0.47 (0.38) n=55 
10 months: 0.52 (0.31) n=50 
 
CBT and TAU for BDI-II results 
CBT BDI-II: 
Baseline: 27.3 
4 months: 18.4 
10 months: 18.3 
TAU BDI-II: 
Baseline: 27.7 
4 months: 20.3 
10 months: 20.8 
Van Straten 
2008(20) 
EQ-5D for intervention groups pre and post intervention 
ĨĨĞĐƚƐŝǌĞ ?ŽŚĞŶ ?Ɛ ?ĨŽƌĂůůƐĐĂůĞƐ 
Mean EQ-5D scores: 
Control pre: 0.61 post: 0.66 
Intervention pre: 0.62 post 0.73 
Intervention complete: pre 0.63 post 0.8 
 
Effect sizes (Cohens d) 
All (n=107), course completers (n=59) 
CES-D 0.5 (0.22-0.79), 0.67 (0.32-1.02) 
MDI 0.33 (0.03-0.63), 0.56 (0.22-0.9) 
SCL-A 0.42 (0.14-0.72), 0.51 (0.18-0.84) 
EQ-5D 0.31 (0.03-0.60), 0.44 (0.11-0.77) 
HADS 0.33 (0.04-0.61), 0.48 (0.15-0.82) 
MBI not significant. 
Sobocki  
2007(22) 
EQ-5D at baseline, first follow-up, 6 months follow-up, last visit Mean EQ-5D scores: 
Baseline: 0.47 
First follow-up: 0.60 
6 months: 0.66 
Last follow-up: 0.69  
Swan 2004(9) EQ-5D at baseline, week 12 and week 26. Improvement in BDI and GSI 
(baseline to week 12, baseline to week 26). 
EQ-5D (n=26) 
Baseline: 0.49 (SE 0.07) (0.34-0.64) 
Week 12: 0.65 (SE 0.06) (0.52-0.79) 
Week 26: 0.68 (SE 0.06) (0.55-0.82) 
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QALY: quality of life years; MADRS: Montgomery-Asberg depression rating scale; CI: confidence interval; EQ-5D: EuroQoL 5 dimensions; ES: effect size; SRM: standardised 
response mean; CGI: clinical global impression scale; VAS: visual analogue scale; BAI: Beck anxiety inventory; BDI: Beck depression inventory; WHOQoL: WHO quality of life; 
BSQ: body shape questionnaire; ACQ: agoraphobic cognitions questionnaire; SF-6D: short-form 6 dimensions; MDD: major depressive disorder; SDS: self-rating depression 
scale; HAM-A: Hamilton anxiety scale; TAU: treatment as usual; MBI, Maslach Burnout Inventory
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Table A7: Fields collected in the psychological therapy NCA 
 
 
 
 
 
 
NAPT BASELINE DATA FIELDS (2
nd
 round questionnaires in appendix) 
SERVICE CONTEXT
 
 11  W 11c decision tree questions (checks eligibility), Number of people in the service who deliver therapy 
for anxiety and depression, Whole Time Equivalents (WTE) the above represent IAPT funding (fully, partly 
or none), Sector managing the service (NHS, voluntary sector, private), Level of service (primary care, 
secondary care, mixture of primary and secondary care), Therapeutic modalities offered by the service for 
anxiety and depression, Age range of patients that are generally seen (working age only, older people 65+ 
only, both working age and older people), Access to therapy in another language than English (through 
therapists and interpretation services) 
THERAPIST QUESTIONNAIRE (Anonymous 
*
mandatory fields 
 What is your service's NAPT code
*
, What is the name of the service you are completing this for*, 
Number and response rate per service, Hours per week working in the service, In an average week, the 
ŶƵŵďĞƌŚŽƵƌƐƐƉĞŶƚŝŶĚŝƌĞĐƚĐŽŶƚĂĐƚǁŝƚŚƉĂƚŝĞŶƚƐ ?dŚĞƌĂƉŝƐƚ ?ƐĐŽƌĞƉƌŽĨĞƐƐŝŽŶ ?ŽĐĐƵƉĂƚŝŽŶ ?dŚĞƌĂƉŝĞƐ
currently delivered and how the therapist developed their expertise (no formal training
*
, working with 
supervision without training, short workshops up to 10 days, formal training completed
*
, currently 
undertaking formal training
*
), Formal training completed (Doctorate, MSc/MA, postgraduate diploma, 
postgraduate certificate, other diploma, other certificate, other), Currently registered as a clinical 
practitioner with a professional body (Yes/No), If yes, the professional bodies are specified 
RETROSPECTIVE AUDIT OF PATIENTS ENDING THERAPY BETWEEN 1 SEPT AND 30 NOV 2010 
 Total number of patients ending therapy during the audit period, Patient's PCT/LHB, Gender, Age in years, 
Ethnic Group, Main / Primary diagnosis, Secondary diagnosis, Date referral received, Date first appt 
offered / made, Date of first appt attended, Purpose of first appointment, Date of first treatment session 
offered / made, Date of first treatment session attended, Date of last attended treatment session, 
Number of therapy sessions attended, Reason why therapy ended (completed treatment, dropped 
out/unscheduled discontinuation, declined treatment, not suitable for service, deceased, unknown), Type 
of therapy provided, Outcome measure(s) used (Yes/No), If yes, scores requested at start of treatment 
and end of treatment; or the last occasion that the scale was rated 
SERVICE USER QUESTIONNAIRE 
  Number and response rate per service 
ACCESS  
  I was referred for talking treatment at the right time (Yes/No), The waiting time for my talking treatment 
to start was reasonable (Yes/No), My appointment was scheduled on a day/time that was convenient to 
me (Yes/No), I was able to get to my appointment location without too much difficulty (Yes/No), I 
received enough information about my talking treatment before it began (Yes/No) 
OUTCOMES  
  This talking treatment helps me to understand my difficulties (Yes/No), I am getting the right kind of help 
(Yes/No), I am receiving the right number of sessions of talking treatment (Yes/No), If I have similar 
difficulties in the future, I would take up this talking treatment again (Yes/No), This talking treatment 
helps me cope with my difficulties (Yes/No) 
ARM-5  
  Individual item scores and total score 
BACKGROUND INFORMATION 
 Age, Gender, Ethnic group, Talking treatment (CBT, MBCT, person centred/humanistic, solution-focused, 
psychodynamic, CAT, counselling, low intensity treatment, other therapy, not sure), Number of sessions 
in the current course of treatment, Waiting time for current talking treatment to start (1 month or less, 1-
3 months, 4-6 months, 7-9 months, 10-12 months, more than 12 months) 
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Table A8: NAPT SECOND ROUND DATA FIELDS (Psychological therapies NCA) 
REGISTRATION FORM
 
  
Baseline participation (Yes and the service is fundamentally the same, Yes but the service has changed, 
No), Sector managing the service (NHS, voluntary sector, private), Level of service (primary care, 
secondary care, mixture of primary and secondary care), IAPT programme (yes, no), Stepped care (yes, 
ŶŽ ?ĚŽŶ ?ƚŬŶŽǁ ? ?,ŽŵĞǀŝƐŝƚƐ ?ǇĞƐ ?ŶŽ ? ?&ŽůůŽǁ-up appointments (yes, no, only when clinically indicated), 
Number of people in the service who deliver therapy for anxiety and depression, Whole Time Equivalents 
(WTE) the above represent, Therapeutic modalities offered by the service for anxiety and depression 
Age range of patients (working age only, older people 65+ only, both working age and older people), 
Number of patients seen in 3 month period (less than 10, 11-50, 51-100, 101-500, 501+), Access to 
therapy in another language than English (yes -through therapists, yes  W through interpretation services, 
no), Structured collection of service user feedback in last year (yes, no) 
RETROSPECTIVE CASE RECORD AUDIT  
(completed by therapist for all service users who ended therapy 1 July-31 October 2012) 
PART A: Unique Identifiers (
*
mandatory fields)   
NAPT Service Code
*
, Patient code
*
, Therapist initials 
PART B: Patient information   
Year of birth, Gender,
*
 Ethnic group
*
  
PART C: Referral (
*
mandatory fields)   
Date referral received, Referral source
*
 
PART D: Reason for therapy (
*
mandatory fields)   
Diagnosis (list of conditions with ICS-10 codes for primary and secondary diagnosis)
*
, Problem for which 
psychological therapy offered
*
 (Same as primary diagnosis, Same as secondary diagnosis, Depression, 
Mixed anxiety and depression, Social phobias, Specific (isolated phobias), Panic disorder (with or without 
agrophobia), Obsessive compulsive disorder, Generalized anxiety disorder, Post-traumatic stress disorder 
Body dysmorphic disorder,, Other anxiety disorder) 
PART E: Appointment dates and Attendance (
*
mandatory fields)   
Date of first appointment attended by service user, What was the reason for this first appointment
*
 
(Assessment only, Treatment only, Assessment and treatment, Not Known), Date of first treatment 
appointment attended by service user, Date of last treatment appointment attended, How many therapy 
sessions did the patient attend, What was the reason for therapy ending*(Completed Treatment, 
Deceased, Declined Treatment, Dropped out of Treatment  (unscheduled discontinuation), Not Suitable 
for the Service, Referral to another Service, Not Known ) 
PART F: Type of therapy (
*
mandatory fields)   
High intensity therapy provided to service user:
*
 (individual/group: Cognitive Behavioural Therapy (CBT), 
Person-Centred (or other Humanistic Therapy), Solution-Focused Therapy, Psychodynamic/Psychoanalytic 
Therapy, Behavioural Activation, Interpersonal Therapy, Cognitive Analytic Therapy (CAT), 
Systemic/Family Therapy, Arts Psychotherapies, Mindfulness-Based Cognitive Therapy, Dialectical 
Behavioural Therapy, Counselling, Eye Movement Desensitisation & Reprocessing Therapy (EMDR), 
Problem-Solving Therapy, Couples Therapy  
Low Intensity therapy provided to service user:
*
 (individual/group: Computerised Cognitive-behavioural 
therapy  Wfacilitated, Guided/Facilitated Self-Help, Psycho-Education, Pure Self-Help (e.g. books on 
prescriptions, unfacilitated cCBT via DVD, etc), Signposting/Referral Facilitation Schemes, Structured 
Exercise, Support and Advice in Adherence of Antidepressant/GP-Prescribed Medication, Other 
PART G: Outcomes (
*
mandatory fields)   
Enter outcomes scores you have for this service user (both first and last score): HADs ( Anxiety, 
Depression Subscales),  PHQ-9,  GAD-7,  W&SAS, CORE-10,  CORE-OM
*
, CES-D,  HoNOS,  BAI,  BDI-II,  
Other Standardised Measures 
THERAPIST SURVEY (completed by someone who provides psychological therapy as part of their role in a service 
registered for NAPT) 
 
  
Service NAPT code*, name of service completing audit for*, Number and response rate per service, Hours 
per week working in the service, In an average week, the number hours spent in direct contact with 
patients, Qualified member of staff or in training, Therapies currently delivered and how the therapist 
developed their expertise (no formal training, working with supervision without training, post-
qualification CPD e.g. short workshops, currently undertaking formal training, formal training 
completed,), Currently registered as a clinical practitioner with a professional body (Yes/No), If yes, the 
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professional bodies are specified, Rating of formal supervision, Annual appraisal (Yes, No, prefer not to 
say), Degree to which organisation supports CPD, Supervision of other psychological therapists (Yes, No, 
prefer not to say), Received training in supervising other psychological therapists (Yes, No, prefer not to 
say) 
TALKING TREATMENT SERVICE USER QUESTIONNAIRE - optional 
ACCESS (all questions use 5 point Likert scale)   
Please indicate if self-referral or referred by someone else, I was referred for talking treatment at the 
right time, The waiting time for my talking treatment to start was reasonable, My appointment was 
scheduled on a day/time that was convenient to me, I was able to get to my appointment location 
without too much difficulty, I received enough information about my talking treatment before it began 
CHOICE   
I was offered choice about the venue where my talking treatment would take place, I was offered choice 
about the time of day my talking treatment would take place, I was offered choice about the gender of 
my therapist, I was offered my talking treatment in another language or with an interpreter, I was offered 
choice about the type of talking treatment I would receive, 4 possible responses including: This was not 
important to me  W I had no strong preference either way, This was important to me and I was given 
enough choice, This was important to me, but I was not given enough choice, unsure 
EXPERIENCE OF THERAPY (all questions use 5 point Likert scale)   
This talking treatment helped me to understand my difficulties, I am getting the right kind of help, I am 
receiving the right number of sessions of talking treatment, If I have similar difficulties in the future, I 
would take up this talking treatment again, This talking treatment helps me cope with my difficulties, I 
feel that my needs were taken seriously, understood and appropriately considered, I have experienced 
lasting bad effects from the treatment, I am asked by the therapist to give feedback on how helpful I am 
finding the treatment, I understand where my information is kept, who can see it and when it might be 
shared 
BACKGROUND INFORMATION   
age, gender, ethnic origin, whether or not have military background, sexuality, disability, therapy 
information (group vs.  individual, type of therapy, number of sessions to date, length of wait, self-
referral   referred by someone else) 
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Table A9: Reports relating to other measures used in psychological therapies, with an emphasis on anxiety 
Source, date Population Method used to reach recommendation Measures recommended Implementation issues 
for large scale use? 
  General methods Psychometric 
properties 
considered? 
Measures 
considered 
  
Oxford PROMS 
group, 
2009(38) 
Anxiety and 
depression 
Selected measures to review 
that have received significant 
recent attention in the NHS 
either through policy or 
professional recommendations 
or frequency of use. Aim to 
identify PROMS for use as 
evidence of quality and 
outcomes of services. 
Considered, 
but not 
defined in 
methods 
section 
PHQ 2 & 9 
BDI-II 
HADS 
Whooley 
questions 
CORE-OM 
BAI 
GAD-7 
WSAS 
EQ-5D 
SF-6D 
 
Several caveats and options were discussed 
in the review, and different options 
recommended for different situations. 
Many PROMS in mental health have not 
been developed with responsiveness (a key 
requirement in assessment of services) in 
mind, but rather as screening/diagnostic 
tools.  
 
For depression: QOF, PHQ-9, BDI-II and 
HADS, though not much evidence about 
responsiveness 
Anxiety: BAI and GAD-7. Even less evidence 
of responsiveness.  
For both: HADS and CORE-OM  W better 
evidence for CORE-OM, also includes social 
function. 
To include social function: WSAS, but little 
research available.  
For preference measure: EQ-5D preferred 
over SF-6D. 
For recovery: more evidence required. 
 
Concluded: Health professionals not 
strongly convinced of the value of PROMS 
in mental health. Debate about usefulness 
of PROMS in mental health is still in earliest 
stages. 
Responsiveness 
evidence is low in 
quantity.  
EMA research 
guideline, 
Generalised 
anxiety 
Expert panel and stakeholder 
consultation: Efficacy working 
Unclear Unclear A rating scale, choice justified according to 
validity and reliability.  
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2005(39) disorder party of  
CHMP 
 
Hamilton anxiety rating scale ( HAM-A) is 
mentioned as being widely used, but not an 
optimal scale, with the total scale as a 
primary endpoint, and the HAM-A psychic 
anxiety factor as a secondary endpoint. 
EMA research 
guideline, 
2005(40) 
Panic 
disorder 
Expert panel and stakeholder 
consultation: Efficacy working 
party of CHMP 
Unclear Unclear A rating scale, choice justified according to 
validity and reliability.  
 
Should include frequency and severity of 
panic attacks, severity of agoraphobic 
avoidance and anticipatory anxiety. 
 
Scales given as examples (i.e. not 
exhaustive list):  
Panic disorder severity scale (PDSS) 
Panic and Agoraphobia Scale (PAS) 
 
An improvement in scale should be 
supported by a relevant decrease in 
frequency and severity of attacks.  
 
EMA research 
guideline, 
2006(41) 
Social 
anxiety 
disorder 
Expert panel and stakeholder 
consultation: Efficacy working 
party of committee for 
medicinal products for human 
use (CHMP) 
Unclear, but 
mentioned for 
one measure. 
Unclear A rating scale, choice justified according to 
validity and reliability.  
 
Scales given as examples (i.e. not 
exhaustive list):  
Liebowitz Social Anxiety scale (LSAS) 
Brief Social Phobia Scale (BSPS) 
 
LSAS most commonly used. Paediatric 
version available. 
 
Self-rated scales include the Social phobia 
and anxiety inventory (SPAI); the social 
phobia inventory (SPIN), which has good 
psychometric properties; the Sheehan 
LSAS and BSPS are 
clinician-administered 
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disability scale (SDS). 
 
Royal College 
of 
Psychiatrists 
guideline(42) 
Adult 
psychiatry 
(section on 
anxiety) 
Methods not described. Unclear Unclear Condition-specific  
scales given as examples (i.e. not 
exhaustive list):  
 
PHQ-9 (Patient Health Questionnaire  W 9) 
A 9-item depression scale assessing 
symptoms and functional impairment to 
make a tentative diagnosis of depression, 
and deriving a severity score to help select 
and monitor treatment.[spitzer 1999] 
 
GAD -7 (Generalised Anxiety Disorder 
Assessment  W 7) 
A self-administered, 7-item patient 
questionnaire used as screening tool and 
severity measure for generalised anxiety 
disorder.[Spitzer 2006] 
 
Clinical Outcomes in Routine Evaluation  ?  
Outcome Measure (CORE-OM) 
A client self-report questionnaire designed 
to be administered before and after 
therapy. The client is asked to respond to 
34 questions about how they have been 
feeling over the past week, using a 5-point 
ƐĐĂůĞƌĂŶŐŝŶŐĨƌŽŵ ?ŶŽƚĂƚĂůů ?ƚŽ ?ŵŽƐƚor all 
ŽĨƚŚĞƚŝŵĞ ? ?dŚĞ ? ?ŝƚĞŵƐĐŽǀĞƌĨŽƵƌ
dimensions: subjective well-being; 
problems/symptoms; life functioning; and 
risk/harm.[Barkham 2001] 
 
Generic HRQoL measures 
Both SF-6D and EQ-5D are recommended. 
Several methods not 
relevant to WP1.2 were 
recommended: 
 
Patient-identified goals 
- can only be assessed 
in an ongoing 
treatment context 
 
Health of the Nation 
Outcome Scale  W 
routinely collected as 
part of the minimum 
mental health data set, 
but is a clinician-
administered measure.  
 
 
Royal College Older adults Authored by a working group Unclear Unclear Recommends   
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of 
Psychiatrists 
guideline(43) 
 
Patient Health Questionnaire  W Generalised 
Anxiety Disorder severity index (GAD-7) 
 
Hospital anxiety and depression scale 
(HADS)  W notes that as it is designed for use 
with patients with physical illnesses, and so 
may miss somatic symptoms, which it is not 
designed to assess.  
EMA: European Medicines Agency; HRQoL: Health related quality of life; CHMP: committee for medicinal products for human use; SF-6D: short form 6 dimensions 
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